8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 11, 2005

Medivation, Inc.

(Exact name of Registrant as Specified in its Charter)

Delaware	000-20837	13-3863260
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

501 Second Street, Suite 211

San Francisco, California 94107

(Address of Principal Executive Offices)

(415) 543-3470

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure

On October 11, 2005, Medivation, Inc. issued two press releases, copies of which are furnished as Exhibit 99.1 and Exhibit 99.2, respectively, to this Form 8-K and are incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.
Exhibit No.	Description
99.1	Press Release dated October 11, 2005
99.2	Press Release dated October 11, 2005

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 11, 2005	MEDIVATION, INC.
	By:	/s/ C. Patrick Machado
	Name:	C. Patrick Machado
	Title:	Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Press Release dated October 11, 2005
99.2	Press Release dated October 11, 2005

EX-99.1

Exhibit 99.1

Contacts:
Medivation, Inc.	Lippert/Heilshorn & Associates
Patrick Machado, Chief Financial Officer	Bruce Voss/Don Markley
(415) 543-3470 x201	(310) 691-7100

MEDIVATION EXPANDS CLINICAL DEVELOPMENT OF DIMEBON TO INCLUDE

HUNTINGTON’S DISEASE

SAN FRANCISCO (October 11, 2005) – Medivation, Inc. (OTCBB: MDVN) today announced that, based on newly received data, it has expanded the clinical development program of its proprietary small molecule Dimebon to include Huntington’s disease.

Huntington’s disease is a neurological disorder characterized clinically by involuntary movements, loss of cognitive function and a wide spectrum of behavioral disorders. There are no FDA-approved therapies to treat Huntington’s disease, and the disease is invariably fatal. According to information on the website of the Hereditary Disease Foundation (www.hdfoundation.org), approximately 30,000 patients currently suffer from Huntington’s disease in the U.S., and an additional 150,000 are genetically at risk for developing it.

Medivation expects to file an investigational new drug application for Huntington’s disease in the first quarter of 2006 and to begin U.S. clinical testing of Dimebon in Huntington’s disease in the second quarter of 2006.

About Medivation

Medivation, Inc. seeks to acquire, develop and sell or partner biomedical technologies in the early-development stage of the research and development process – the stage beginning with the identification of a specific biomedical product candidate with a demonstrated scientific rationale for further development, and ending upon the completion of Phase II clinical trials designed to provide evidence of potential safety and efficacy in patients.

Safe Harbor

This press release contains forward-looking statements, including statements regarding the anticipated timing of regulatory and clinical milestones on our Dimebon Huntington’s disease program, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties that could cause actual results to differ significantly from those projected. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2004 and our Quarterly Reports on Form 10-QSB for the quarters ended March 31, 2005 and June 30, 2005, include more information about factors that could affect our financial and operating results.

# # #

EX-99.2

Exhibit 99.2

Contacts:
Medivation, Inc.	Lippert/Heilshorn & Associates
Patrick Machado, Chief Financial Officer	Bruce Voss/Don Markley
(415) 543-3470 x201	(310) 691-7100

MEDIVATION FILES REGISTRATION STATEMENT FOR

UNDERWRITTEN FOLLOW-ON OFFERING

SAN FRANCISCO (October 11, 2005) – Medivation, Inc. (OTCBB: MDVN) filed a Registration Statement on Form SB-2 on October 6, 2005 for a proposed offering by the Company of 8,700,000 shares of its common stock. The Company expects to grant the underwriter an option to purchase an additional 1,305,000 shares of its common stock to cover over-allotments, if any.

Adams Harkness, Inc. is acting as the underwriter of the proposed offering. The offering of the securities is made only by means of a prospectus, copies of which may be obtained, when available, from Adams Harkness, Inc., Capital Markets Desk, 99 High Street, 12th Floor, Boston, Massachusetts 02110, telephone 1-800-225-6201.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state.

About Medivation

Medivation, Inc. seeks to acquire, develop and sell or partner biomedical technologies in the early-development stage of the research and development process – the stage beginning with the identification of a specific biomedical product candidate with a demonstrated scientific rationale for further development, and ending upon the completion of Phase II clinical trials designed to provide evidence of potential safety and efficacy in patients.

# # #